Merck Serono to Spin Off Parkinson's R&D - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Serono to Spin Off Parkinson's R&D


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck Serono, a division of Merck KGaA, announced in June, 2012 that it would be closing down operations in Geneva, Switzerland as part of its restructuring activities, but providing up to EUR 30 million ($36.9 million) in funding for start-up companies to reemploy some of those displaced workers. The first such start-up was announced on Jul. 30, 2012, funded by EUR 2.1 million ($2.57 million) in seed money from Merck Serono’s Entrepreneur Partnership Program.

The new company, Prexton Therapeutics, will employ Merck Serono scientists to continue work around Merck Serono’s R&D portfolio in the field of Parkinson’s disease. Its programs will leverage Merck Serono’s portfolio of compounds targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics plans to develop the mGluR programs from lead optimization up to clinical Phase I and will look for partnership and licensing opportunities for further development.

According to François Naef, chairman of the board of directors of Merck Serono, “We are really proud and satisfied that this first project is now coming to life. Through such initiatives, not only will we be able to maintain jobs in the Geneva area but also unique expertise.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here